Market Overview

UPDATE: Credit Suisse Downgrades Spectrum Pharmaceuticals on Limited Growth Opportunities and Increased Risk

Related SPPI
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)
Mallinckrodt Earnings Beat, Shares Dip on Low Revs - Analyst Blog

In a report published Monday, Credit Suisse analyst Jason Kantor downgraded Spectrum Pharmaceuticals (NASDAQ: SPPI) from Neutral to Underperform and maintained a price target of $7.00.

In the report, Credit Suisse cited, “We believe the near term growth opportunities are limited, and there is risk to current company Fusilev guidance. Specifically, Fusilev Q2 sales and H2 run rate are likely to disappoint. Belinostat should provide a new source of growth, but not in 2013 and there still are regulatory risks associated with the program.”

Spectrum closed Friday at $8.01.

Posted-In: Credit Suisse Jason KantorAnalyst Color Downgrades Analyst Ratings

 

Most Popular

Related Articles (SPPI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional